Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Active MMP-8 (aMMP-8) as a Grading and Staging Biomarker in the Periodontitis Classification

Timo Sorsa, Saeed Alassiri, Andreas Grigoriadis and 5 more

Diagnostics · 2020 · CC BY

doi:10.3390/diagnostics10020061

Abstract

The aim of this study was to investigate the utility of incorporating active matrix metalloproteinase-8 (aMMP-8) as a biomarker into the new periodontitis classification system (stage/grade) presented in 2018. This study included 150 Greek adults aged 25–78, of whom 74 were men and 76 women. Participants were tested with an aMMP-8 point-of-care mouthrinse test, after which a full-mouth clinical examination was performed to assess their periodontal and oral health. The aMMP-8 levels in mouthrinse were significantly lower among healthy patients compared with patients in more severe periodontitis stages and grades (Kruskal–Wallis test and Dunn–Bonferroni test for pairwise post-hoc comparisons; p < 0.01 and p < 0.05, respectively). Furthermore, aMMP-8 levels were less correlated with plaque levels than bleeding on probing (BOP) (Spearman’s rho = 0.269, p < 0.001; Spearman’s rho = 0.586, p < 0.001); respectively). Thus, aMMP-8 was more robust to the confounding effects of oral hygiene than traditional periodontal parameter bleeding on probing. The aMMP-8 point-of-care mouthrinse test can be utilized as an adjunctive and preventive diagnostic tool to identify periodontal disease, classified by stage and grade, and ongoing periodontal breakdown chairside in clinical practice in only 5 min. Overall, integrating aMMP-8 into the new periodontitis classification system seems beneficial.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Main text

A new revised periodontitis case definition system was introduced in 2018 to define periodontitis more appropriately by its stage (the severity and extent of periodontal tissue destruction and complexity of management), and grade (the future risk of progression). One of its main goals is to provide dentists a framework for individualized identification, treatment and prevention of periodontitis in patients. In addition, it provides a necessary and very much needed framework for the introduction of diagnostic and prognostic biomarkers to extend and improve the information provided by the standard clinical measures.

As Tonetti et al. note, there are some limitations regarding reliance on bleeding on probing (BOP) and other traditional measures in periodontitis diagnostics. For example, some of them are very much influenced by the level of training and experience of operator (i.e., periodontal probing). Furthermore, the clinical measurements provide mainly retrospective evidence of the severity and extent of periodontal breakdown but are limited methods to assess and predict the risk for on-going and future periodontal breakdown. That stems from the nature of periodontitis to progress episodically, as the quiescent and active periods alternate. Periodontal breakdown does not always follow such geometric or arithmetic calculations or linear patterns that are accurately measurable by radiographic bone loss and/or clinical attachment loss (CAL).

The new periodontitis classification system includes grading parameters to assess the future risk of periodontitis progression. Although they are associated with periodontitis and increase the likelihood of future periodontal breakdown, they cannot be considered to be reliable enough to indicate when periodontitis is in its active phase. This applies to even the grade modifiers smoking and diabetes that are well-known risk factors for periodontitis. The current grading parameters are mainly able to predict that it is likely that the periodontal breakdown occurs in the future, but not the exact time when it is occurring. In this regard, the future inclusion of more robust biomarkers to the classification system is still anticipated in order to identify patients in active periods of periodontitis (= ongoing periodontal breakdown) and to be able to monitor disease progression and treatment responses more accurately.

Oral fluids have been studied intensively to find suitable biomarkers from saliva and gingival crevicular fluid (GCF) for the diagnostics of periodontitis. One of the most studied biomarkers is matrix metalloproteinase-8 (MMP-8). Several studies (for example Lee et al., Romanelli et al., Kiili et al., Sorsa et al., and Alassiri et al.) have demonstrated how elevated levels of active matrix metalloproteinase-8 (aMMP-8), but not total or latent MMP-8, differentiate periodontitis from gingivitis, and precede periodontal attachment loss. Furthermore, active periodontal tissue destruction in progress (i.e., the active phase of periodontal disease) can be identified non-invasively in oral fluids as a pathological elevation of aMMP-8 levels. Thus, it is no surprise that the aMMP-8 chairside/point-of-care (PoC) oral fluid tests have continuously been successful in identifying active periodontal tissue destruction and active periodontal disease (periodontitis, peri-implantitis, subclinical periodontitis) among adults and adolescents of different ethnic populations. Similarly, previous longitudinal studies have shown that aMMP-8 assays with the same antibody can be used for predicting the progression of periodontitis and attachment loss, and monitoring treatment of periodontitis during the maintenance phase.

Many other potential biomarkers to detect periodontitis and related systemic diseases have been investigated as well; these include, along with others, asymmetric dimethylarginine (ADMA), C-reactive protein, interferon gamma (IFN-γ), interleukin-6 (IL-6), macrophage inflammatory protein-1α (MIP-1α), PMN elastase, vitamin C and also antioxidants. For example, vitamin C is linked to oxidative MMP-activation cascade by its recorded ability to prevent the oxidative activation of proMMP-8. According to a recent systematic review, aMMP-8/MMP-8 is currently the most accurate diagnostic biomarker in GCF for periodontitis in systemically healthy patients. In saliva, aMMP-8/MMP-8 is also among the best five biomarkers, and the combination of aMMP-8/MMP-8 and IL-6 seems the most promising salivary diagnostic marker for periodontitis.

In this short communication, the aim is to study the usefulness of aMMP-8 as the stage and grade biomarker for the new periodontitis classification system. Our hypothesis is that aMMP-8 levels among 150 Greek adults, measured by a quantitative aMMP-8 point-of-care (PoC)/chairside mouthrinse test, are positively associated with the severity of periodontal disease (stage) and possible risk for disease progression (grade).

Figure 1 demonstrates the aMMP-8 levels, as well as bleeding on probing (BOP), and visual plaque index (VPI) levels among 150 Greek patients classified by the new classification system. The participants were selected among the patients of the Periodontology University Clinic, Thessaloniki, Greece, as described earlier. They had no underlying diseases and no medications (antibiotics, anti-inflammatory drugs etc.) were in use for the last 3 months before their examination (more information about patient characteristics in Table 1). Patients’ aMMP-8 levels were determined by the aMMP-8 PoC/chairside mouthrinse test, PerioSafe®, in combination with a digital reader, ORALyzer®, following the manufacturer’s instructions. A.G. performed a full-mouth clinical examination for each patient to assess their periodontal and oral health, after which each patient’s aMMP-8 mouthrinse test result was read.

Firstly, aMMP-8 levels in mouthrinse were significantly lower among healthy patients compared with patients in more severe periodontitis stages and grades (Kruskal–Wallis test, p < 0.01; Figure 1), as would be expected from an effective diagnostic tool to classify periodontal health and disease. This result is also in agreement with previous studies that have shown that aMMP-8 predicts very well future periodontal breakdown (positive predictive values range between 81.8%–94.7%). Secondly, BOP and VPI levels were also associated with the periodontitis stage and grade (Kruskal–Wallis test, p < 0.01); Figure 1), but these two parameters were also moderately correlated with each other (Spearman’s rho = 0.586, p < 0.001). The association between dental plaque levels and BOP levels and their potential confounding is well understood in the literature. Previous studies have also shown that BOP poorly predicts future periodontal breakdown (positive predictive value for repeated incidence of BOP was ≤ 30%), but the continuous absence of BOP correlates much better with periodontal stability. For example, Joss et al. suggested a cut-off of 20% for BOP, while in the new classification system a threshold of 10% for BOP is suggested to define periodontal health. However, as Figure 1 shows, despite the positive association between BOP and both stage and grade, the two cut-offs are likely to cause a large number of false positives. This seems to apply to VPI as well (see Figure 1), for example, when considering a good oral hygiene as a prerequisite for periodontal health and using a low cut-off for VPI. It is noteworthy that plaque assessments are not considered as an effective measure of periodontitis. According to Lang et al., dental plaque determines only 20% of the direct risk of the development of periodontitis.

Finally, in this sample, the range of BOP and VPI levels were wide among healthy patients compared with the diseased patients (stage I–III and Grades A–C). Regarding periodontitis patients, the same applies to BOP and VPI levels among Grade A patients when compared to Grade B patients (Figure 1). This kind of overlapping in BOP and VPI levels between different categories increases the risk for false positive diagnosis, as well. In contrast, the aMMP-8 levels did not exhibit similar overlapping, as BOP and VPI, between the same groups. Furthermore, aMMP-8 levels seemed much more immune to the confounding effects of dental plaque, as the link between aMMP-8 and VPI was somewhat negligible (Spearman’s rho = 0.269, p < 0.001). All in all, aMMP-8 was the preferable method for differentiating periodontal health and disease, because the risk of false positives seemed generally much lower for aMMP-8 than BOP or VPI (see Figure 1).

Our findings indicate that the aMMP-8 mouthrinse PoC/chairside test can be implemented as the staging and grading biomarker in the new classification system of periodontitis. In this regard, a previous study by Räisänen et al. showed that mouthrinse aMMP-8 measurements are better and more precise in identifying periodontal health and disease among adolescents in comparison to saliva aMMP-8 measurements. The same result was repeated and further extended in this study by comparing the aMMP-8 PoC/chairside mouthrinse test to salivary aMMP-8 time-resolved immunofluorometric assay (IFMA) measurements, both methods utilizing the same antibody, among this sample of Greek adults (see Figure 2). The mouthrinse aMMP-8 measurements performed more precisely and gave no false positives (i.e., no positive aMMP-8 mouthrinse test results among healthy patients). In contrast, IFMA measurements of aMMP-8 levels in saliva offered a less definite classification of periodontal health and disease (Figure 2). As Räisänen et al. suggest, mouthrinse aMMP-8 measurements seem the optimal way of measuring the active periodontal breakdown and risk of the future progression of periodontal disease.

The utility of mouthrinse measurements is based on a simple technique to collect and sample gingival crevicular fluid (GCF), instead of using more laborious filter papers or micropipettes. Moreover, previous studies have also presented a better diagnostic accuracy value of GCF in aMMP-8 measurements in comparison to saliva when classifying periodontal health and disease. However, it should also be noted that not all commercial kits detect active forms of MMP-8, as the aMMP-8 PoC mouthrinse test and IFMA used in this study do. Instead, some of them detect the total MMP-8, which is not able to detect periodontal breakdown or progression of periodontitis. This fact may explain the variation in aMMP-8 and MMP-8 results in the literature, in addition to the type of oral fluid used in the testing.

Based on this evidence, therefore, we strongly support the call of Tonetti et al. for a paradigm shift to also consider periodontitis in terms of the inflammatory mediators that are immunoassay measures, offering information that traditionally used diagnostic methods are not able to provide as accurately. We propose aMMP-8 as the biomarker and the aMMP-8 PoC/chairside mouthrinse testing to be incorporated into the new periodontal disease classification system by Tonetti et al. (see Table 2: modified from Tonetti et al.), to improve the diagnostic accuracy of periodontal diseases and their progression. The proposed aMMP-8 measurements by an aMMP-8 PoC mouthrinse test with a cut-off of 20 ng/mL allows this risk to be measured early enough, effectively and non-invasively in clinical practice within 5 min without the need to use laborious and time-consuming laboratory equipment. The ability to identify active periods of periodontitis (=ongoing periodontal breakdown) chairside and in real-time is of great value to dentists trying to optimize patient treatment. It lets them to monitor disease progression, and treatment responses, which should translate to better treatment outcomes as well. After all, periodontitis does have a negative effect not only to periodontium but also to the whole body by increasing the systemic inflammatory burden and the risk for certain systemic diseases like diabetes. Finally, in addition to periodontitis, several studies have reported elevated aMMP-8 levels among patients with diabetes (type 1 and 2). In this regard, the recent study by Grigoriadis et al. demonstrated that aMMP-8 PoC mouthrinse testing is also suitable for prediabetes/diabetes screening at the dental office.

2. Patents

Timo Sorsa and Dirk-Rolf Gieselmann are inventors of US-patent 10 488 415 B2 and a Japanese patent 2016-554676.

References 62

  1. 1.

    Tonetti M.S., Greenwell H., Kornman K.S. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J. Clin. Periodontol. 2018;45(Suppl. S20):S149-S161.

    Not in our library10.1111/jcpe.12945

  2. 2.

    Kinane D.F., Stathopoulou P.G., Papapanou P.N. Periodontal diseases. Nat. Rev. Dis. Primers. 2017;3:17038.

    Not in our library10.1038/nrdp.2017.38

  3. 3.

    Leite F.R.M., Nascimento G.G., Scheutz F., López R. Effect of Smoking on Periodontitis: A Systematic Review and Meta-regression. Am. J. Prev. Med. 2018;54:831-841.

    Not in our library10.1016/j.amepre.2018.02.014

  4. 4.

    Cervino G., Terranova A., Briguglio F., De Stefano R., Famà F., D’Amico C., Amoroso G., Marino S., Gorassini F., Mastroieni R., et al. Diabetes: Oral Health Related Quality of Life and Oral Alterations. Biomed. Res. Int. 2019;2019:5907195.

    Not in our library10.1155/2019/5907195

  5. 5.

    Nascimento G.G., Leite F.R.M., Vestergaard P., Scheutz F., López R. Does diabetes increase the risk of periodontitis? A systematic review and meta-regression analysis of longitudinal prospective studies. Acta Diabetol. 2018;55:653-667.

    Not in our library10.1007/s00592-018-1120-4

  6. 6.

    Lee W., Aitken S., Sodek J., McCulloch C.A. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: Role of active enzyme in human periodontitis. J. Periodontal. Res. 1995;30:23-33.

    Not in our library10.1111/j.1600-0765.1995.tb01249.x

  7. 7.

    Romanelli R., Mancini S., Laschinger C., Overall C.M., Sodek J., McCulloch C.A. Activation of Neutrophil Collagenase in Periodontitis. Infect. Immun. 1999;67:2319-2326.

    Not in our library10.1128/iai.67.5.2319-2326.1999

  8. 8.

    Kiili M., Cox S.W., Chen H.Y., Wahlgren J., Maisi P., Eley B.M., Salo T., Sorsa T. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: Molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J. Clin. Periodontol. 2002;29:224-232.

    Not in our library10.1034/j.1600-051x.2002.290308.x

  9. 9.

    Sorsa T., Tjäderhane L., Konttinen Y.T., Lauhio A., Salo T., Lee H.M., Golub L.M., Brown D.L., Mäntylä P. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann. Med. 2006;38:306-321.

    Not in our library10.1080/07853890600800103

  10. 10.

    Alassiri S., Parnanen P., Rathnayake N., Johannsen G., Heikkinen A.M., Lazzara R., van der Schoor P., van der Schoor J.G., Tervahartiala T., Gieselmann D., et al. The Ability of Quantitative, Specific, and Sensitive Point-of-Care/Chair-Side Oral Fluid Immunotests for aMMP-8 to Detect Periodontal and Peri-Implant Diseases. Dis. Mark. 2018;2018:1306396.

    Not in our library10.1155/2018/1306396

  11. 11.

    Sorsa T., Gürsoy U.K., Nwhator S., Hernandez M., Tervahartiala T., Leppilahti J., Gürsoy M., Könönen E., Emingil G., Pussinen P.J., et al. Analysis of Matrix Metalloproteinases, Especially MMP-8, in Gingival Crevicular Fluid, Mouthrinse and Saliva for Monitoring Periodontal Diseases. Periodontol. 2000. 2016;70:142-163.

    Not in our library10.1111/prd.12101

  12. 12.
    Matrix Metalloproteinase-8 as an Inflammatory and Prevention Biomarker in Periodontal and Peri-Implant Diseases · 2018
    Not checked
  13. 13.

    Zhang L., Li X., Yan H., Huang L. Salivary matrix metalloproteinase (MMP)-8 as a biomarker for periodontitis: A PRISMA-compliant systematic review and meta-analysis. Medicine. 2018;97:e9642.

    Not in our library10.1097/md.0000000000009642

  14. 14.

    Nwhator S.O., Ayanbadejo P.O., Umeizudike K.A., Opeodu O.I., Agbelusi G.A., Olamijulo J.A., Arowojolu M.O., Sorsa T., Babajide B.S., Opedun D.O. Clinical correlates of a lateral-flow immunoassay oral risk indicator. J. Periodontol. 2014;85:188-194.

    Not in our library10.1902/jop.2013.130116

  15. 15.

    Izadi Borujeni S., Mayer M., Eickholz P. Activated matrix metalloproteinase-8 in saliva as diagnostic test for periodontal disease? A case-control study. Med. Microbiol. Immunol. 2015;204:665-672.

    Not in our library10.1007/s00430-015-0413-2

  16. 16.

    Johnson N., Ebersole J.L., Kryscio R.J., Danaher R.J., Dawson D., Al-Sabbagh M., Miller C.S. Rapid assessment of salivary MMP-8 and periodontal disease using lateral flow immunoassay. Oral Dis. 2016;22:681-687.

    Not in our library10.1111/odi.12521

  17. 17.

    Heikkinen A.M., Nwhator S.O., Rathnayake N., Mäntylä P., Vatanen P., Sorsa T. Pilot study on oral health status as assessed by an active matrix metalloproteinase-8 chairside mouthrinse test in adolescents. J. Periodontol. 2016;87:36-40.

    Not in our library10.1902/jop.2015.150377

  18. 18.

    Heikkinen A.M., Raivisto T., Kettunen K., Kovanen L., Haukka J., Pakbaznejad Esmaeili E., Elg J., Gieselmann D.R., Rathnayake N., Ruokonen H., et al. Pilot study on the genetic background of an active matrix metalloproteinase-8 test in Finnish adolescents. J. Periodontol. 2017;88:464-472.

    Not in our library10.1902/jop.2016.160441

  19. 19.

    Lorenz K., Keller T., Noack B., Freitag A., Netuschil L., Hoffmann T. Evaluation of a novel point-of-care test for active matrix metalloproteinase-8: Agreement between qualitative and quantitative measurements and relation to periodontal inflammation. J. Periodontal Res. 2017;52:277-284.

    Not in our library10.1111/jre.12392

  20. 20.

    Leppilahti J.M., Harjunmaa U., Järnstedt J., Mangani C., Hernández M., Tervahartiala T., Lopez R., Ashorn U., Ashorn P., Gieselmann D.R., et al. Diagnosis of newly delivered mothers for periodontitis with a novel oral-rinse aMMP-8 point-of-care test in a rural Malawian population. Diagnostics. 2018;8:67.

    Not in our library10.3390/diagnostics8030067

  21. 21.

    Räisänen I.T., Heikkinen A.M., Nwhator S.O., Umeizudike K.A., Tervahartiala T., Sorsa T. On the diagnostic discrimination ability of mouthrinse and salivary aMMP-8 point-of-care testing regarding periodontal health and disease. Diagn. Microbiol. Infect. Dis. 2019;95:114871.

    Not in our library10.1016/j.diagmicrobio.2019.114871

  22. 22.

    Räisänen I.T., Heikkinen A.M., Pakbaznejad Esmaeili E., Tervahartiala T., Pajukanta R., Silbereisen A., Bostanci N., Sorsa T. A point-of-care test of active matrix metalloproteinase-8 (aMMP-8) predicts triggering receptor expressed on myeloid cells-1 (TREM-1) levels in saliva. J. Periodontol. 2019.

    Not in our library10.1002/jper.19-0132

  23. 23.

    Räisänen I.T., Heikkinen A.M., Siren E., Tervahartiala T., Gieselmann D.R., van der Schoor G.J., van der Schoor P., Sorsa T. Point-of-care/chairside aMMP-8 analytics of periodontal diseases’ activity and episodic progression. Diagnostics. 2018;8:74.

    Not in our library10.3390/diagnostics8040074

  24. 24.

    Räisänen I.T., Sorsa T., van der Schoor G.-J., Tervahartiala T., van der Schoor P., Gieselmann D.R., Heikkinen A.M. Active matrix metalloproteinase-8 point-of-care (PoC)/chairside mouthrinse test vs bleeding on probing in diagnosing subclinical periodontitis in adolescents. Diagnostics. 2019;9:34.

    Not in our library10.3390/diagnostics9010034

  25. 25.

    Schmalz G., Hübscher A.E., Angermann H., Schmidt J., Schmickler J., Legler T.J., Ziebolz D. Associations of chairside salivary aMMP-8 findings with periodontal parameters, potentially periodontal pathogenic bacteria and selected blood parameters in systemically healthy adults. Diagn. Microbiol. Infect. Dis. 2019;95:179-184.

    Not in our library10.1016/j.diagmicrobio.2019.05.006

  26. 26.

    Grigoriadis A., Sorsa T., Räisänen I., Pärnänen P., Tervahartiala T., Sakellari D. Prediabetes/diabetes can be screened at the dental office by a low-cost and fast chair-side/point-of-care aMMP-8 immunotest. Diagnostics. 2019;9:151.

    Not in our library10.3390/diagnostics9040151

  27. 27.

    Mäntylä P., Stenman M., Kinane D.F., Tikanoja S., Luoto H., Salo T., Sorsa T. Gingival crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of periodontitis. J. Periodontal Res. 2003;38:436-439.

    Not in our library10.1034/j.1600-0765.2003.00677.x

  28. 28.

    Mäntylä P., Stenman M., Kinane D., Salo T., Suomalainen K., Tikanoja S., Sorsa T. Monitoring periodontal disease status in smokers and nonsmokers using a gingival crevicular fluid matrix metalloproteinase-8-specific chair-side test. J. Periodontal Res. 2006;41:503-512.

    Not in our library10.1111/j.1600-0765.2006.00897.x

  29. 29.

    Sorsa T., Hernández M., Leppilahti J., Munjal S., Netuschil L., Mäntylä P. Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods. Oral Dis. 2010;16:39-45.

    Not in our library10.1111/j.1601-0825.2009.01603.x

  30. 30.

    Sorsa T., Mäntylä P., Tervahartiala T., Pussinen P.J., Gamonal J., Hernandez M. MMP activation in diagnostics of periodontitis and systemic inflammation. J. Clin. Periodontol. 2011;38:817-819.

    Not in our library10.1111/j.1600-051x.2011.01753.x

  31. 31.

    Leppilahti J.M., Kallio M.A., Tervahartiala T., Sorsa T., Mäntylä P. Gingival crevicular fluid matrix metalloproteinase-8 levels predict treatment outcome among smokers with chronic periodontitis. J. Periodontol. 2014;85:250-260.

    Not in our library10.1902/jop.2013.130156

  32. 32.

    Leppilahti J.M., Hernández-Ríos P.A., Gamonal J.A., Tervahartiala T., Brignardello-Petersen R., Mantyla P., Sorsa T., Hernández M. Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid provide site-specific diagnostic value for chronic periodontitis. J. Clin. Periodontol. 2014;41:348-356.

    Not in our library10.1111/jcpe.12223

  33. 33.

    Leppilahti J.M., Sorsa T., Kallio M.A., Tervahartiala T., Emingil G., Han B., Mäntylä P. The utility of gingival crevicular fluid matrix metalloproteinase-8 response patterns in prediction of site-level clinical treatment outcome. J. Periodontol. 2015;86:777-787.

    Not in our library10.1902/jop.2015.140421

  34. 34.

    Raivisto T., Sorsa T., Räisänen I., Kauppila T., Ruokonen H., Tervahartiala T., Haukka J., Heikkinen A.M. Active Matrix Metalloproteinase-8 Chair Side Mouth Rinse Test, Health Behaviour and Oral Health in Finnish Adolescent Cohort. J. Clin. Diagn. Res. 2019.

    Not in our library10.7860/jcdr/2020/43031.13467

  35. 35.

    Arias-Bujanda N., Regueira-Iglesias A., Balsa-Castro C., Nibali L., Donos N., Tomás I. Accuracy of single molecular biomarkers in gingival crevicular fluid for the diagnosis of periodontitis: A systematic review and meta-analysis. J. Clin. Periodontol. 2019;46:1166-1182.

    Not in our library10.1111/jcpe.13188

  36. 36.

    Arias-Bujanda N., Regueira-Iglesias A., Balsa-Castro C., Nibali L., Donos N., Tomás I. Accuracy of single molecular biomarkers in saliva for the diagnosis of periodontitis: A systematic review and meta-analysis. J. Clin. Periodontol. 2020;47:2-18.

    Not in our library10.1111/jcpe.13202

  37. 37.

    Sukriti K.C., Wang X.Z., Gallagher J.E. Diagnostic sensitivity and specificity of host-derived salivary biomarkers in periodontal disease amongst adults: Systematic review. J. Clin. Periodontol. 2019.

    Not in our library10.1111/jcpe.13218

  38. 38.
    Targeted salivary biomarkers for discrimination of periodontal health and disease(s) · 2015
    No notice
  39. 39.

    Fiorillo L., Cervino G., Herford A.S., Lauritano F., D’Amico C., Lo Giudice R., Laino L., Troiano G., Crimi S., Cicciù M. Interferon Crevicular Fluid Profile and Correlation with Periodontal Disease and Wound Healing: A Systemic Review of Recent Data. Int. J. Mol. Sci. 2018;19:1908.

    Not in our library10.3390/ijms19071908

  40. 40.

    Isola G., Polizzi A., Muraglie S., Leonardi R., Lo Giudice A. Assessment of Vitamin C and Antioxidant Profiles in Saliva and Serum in Patients with Periodontitis and Ischemic Heart Disease. Nutrients. 2019;11:2956.

    Not in our library10.3390/nu11122956

  41. 41.

    Isola G., Alibrandi A., Currò M., Matarese M., Ricca S., Matarese G., Ientile R., Kocher T. Evaluation of salivary and serum ADMA levels in patients with periodontal and cardiovascular disease as subclinical marker of cardiovascular risk. J. Periodontol. 2020.

    Not in our library10.1002/jper.19-0446

  42. 42.

    Gul S.S., Douglas C.W.I., Griffiths G.S., Rawlinson A. A pilot study of active enzyme levels in gingival crevicular fluid of patients with chronic periodontal disease. J. Clin. Periodontol. 2016;43:629-636.

    Not in our library10.1111/jcpe.12568

  43. 43.

    Tada A., Miura H. The Relationship between Vitamin C and Periodontal Diseases: A Systematic Review. Int. J. Environ. Res. Public Health. 2019;16:2472.

    Not in our library10.3390/ijerph16142472

  44. 44.

    Suomalainen K., Sorsa T., Lindy O., Saari H., Konttinen Y.T., Uitto V.J. Hypochlorous acid induced activation of human neutrophil and gingival crevicular fluid collagenase can be inhibited by ascorbate. Scand. J. Dent. Res. 1991;99:397-405.

    Not in our library10.1111/j.1600-0722.1991.tb01047.x

  45. 45.

    Lang N.P., Bartold P.M. Periodontal health. J. Periodontol. 2018;89(Suppl. S1):S9-S16.

    Not in our library10.1002/jper.16-0517

  46. 46.

    Lang N.P., Joss A., Orsanic T., Gusberti F.A., Siegrist B.E. Bleeding on probing. A predictor for the progression of periodontal disease? J. Clin. Periodontol. 1986;13:590-596.

    Not in our library10.1111/j.1600-051x.1986.tb00852.x

  47. 47.

    Lang N.P., Adler R., Joss A., Nyman S. Absence of bleeding on probing. An indicator of periodontal stability. J. Clin. Periodontol. 1990;17:714-721.

    Not in our library10.1111/j.1600-051x.1990.tb01059.x

  48. 48.

    Joss A., Adler R., Lang N.P. Bleeding on probing. A parameter for monitoring periodontal conditions in clinical practice. J. Clin. Periodontol. 1994;21:402-408.

    Not in our library10.1111/j.1600-051x.1994.tb00737.x

  49. 49.

    Tonetti M.S., Sanz M. Implementation of the new classification of periodontal diseases: Decision-making algorithms for clinical practice and education. J. Clin. Periodontol. 2019;46:398-405.

    Not in our library10.1111/jcpe.13104

  50. 50.

    Claffey N., Nylund K., Kiger R., Garrett S., Egelberg J. Diagnostic predictability of scores of plaque, bleeding, suppuration and probing depth for probing attachment loss. 3 1/2 years of observation following initial periodontal therapy. J. Clin. Periodontol. 1990;17:108-114.

    Not in our library10.1111/j.1600-051x.1990.tb01071.x

  51. 51.

    Grossi S.G., Zambon J.J., Ho A.W., Koch G., Dunford R.G., Machtei E.E., Norderyd O.M., Genco R.J. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J. Periodontol. 1994;65:260-267.

    Not in our library10.1902/jop.1994.65.3.260

  52. 52.

    Hujoel P.P., Cunha-Cruz J., Loesche W.J., Robertson P.B. Personal oral hygiene and chronic periodontitis: A systematic review. Periodontol. 2000. 2005;37:29-34.

    Not in our library10.1111/j.1600-0757.2004.03795.x

  53. 53.

    Gangbar S., Overall C.M., McCulloch C.A., Sodek J. Identification of polymorphonuclear leukocyte collagenase and gelatinase activities in mouthrinse samples: Correlation with periodontal disease activity in adult and juvenile periodontitis. J. Periodontal. Res. 1990;25:257-267.

    Not in our library10.1111/j.1600-0765.1990.tb00914.x

  54. 54.

    Rathnayake N., Gieselmann D.R., Heikkinen A.M., Tervahartiala T., Sorsa T. Salivary diagnostics-point-of-care diagnostics of MMP-8 in dentistry and medicine. Diagnostics. 2017;7:7.

    Not in our library10.3390/diagnostics7010007

  55. 55.

    Leppilahti J.M., Ahonen M.M., Hernández M., Munjal S., Netuschil L., Uitto V.J., Mäntylä P. Oral rinse MMP-8 point-of-care immuno test identifies patients with strong periodontal inflammatory burden. Oral Dis. 2011;17:115-122.

    Not in our library10.1111/j.1601-0825.2010.01716.x

  56. 56.

    Romero-Castro N.S., Vázquez-Villamar M., Muñoz-Valle J.F., Reyes-Fernández S., Serna-Radilla V.O., García-Arellano S., Castro-Alarcón N. Relationship between TNF-α, MMP-8, and MMP-9 levels in gingival crevicular fluid and the subgingival microbiota in periodontal disease. Odontology. 2019.

    Not in our library10.1007/s10266-019-00435-5

  57. 57.

    Sorsa T., Gieselmann D.-R., Korvuo A., Maier K., Mäntylä P., Råman I., Tiisala S. MMP-8 Activation Product, Its Determination and Use. U.S. Patent. 2019.

    Not in our library

  58. 58.
    Oral Health: The First Step to Well-Being · 2019
    No notice
  59. 59.

    Sorsa T., Ingman T., Suomalainen K., Halinen S., Saari H., Konttinen Y.T., Uitto V.-J., Golub L.M. Cellular source and tetracycline-inhibition of gingival crevicular fluid collagenase of patients with labile diabetes mellitus. J. Clin. Periodontol. 1992;19:146-149.

    Not in our library10.1111/j.1600-051x.1992.tb00454.x

  60. 60.

    Ryan M.E., Ramamurthy N.S., Sorsa T., Golub L.M. MMP-mediated events in diabetes. Ann. N. Y. Acad. Sci. 1999;878:311-334.

    Not in our library10.1111/j.1749-6632.1999.tb07692.x

  61. 61.

    Safkan-Seppälä B., Sorsa T., Tervahartiala T., Beklen A., Konttinen Y.T. Collagenases in gingival crevicular fluid in type 1 diabetes mellitus. J. Periodontol. 2006;77:189-194.

    Not in our library10.1902/jop.2006.040322

  62. 62.
    Salivary Biomarkers for Detection of Systemic Diseases · 2013
    No notice

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.